Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial.

The Journal of infectious diseases - 15 Oct 2014

Liegler Teri, Abdel-Mohsen Mohamed, Bentley L Gordon, Atchison Robert, Schmidt Timothy, Javier Jacqueline, Mehrotra Megha, Eden Christopher, Glidden David V, McMahan Vanessa, Anderson Peter L, Li Peilin, Wong Joseph K, Buchbinder Susan, Guanira Juan V, Grant Robert M

Abstract excerpt

BACKGROUND: The iPrEx study demonstrated that combination oral emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) as preexposure prophylaxis (PrEP) protects against HIV acquisition in men who have sex with men and transgender women. Selection for drug resistance could offset PrEP benefits. METHODS: Phenotypic and genotypic clinical resistance assays characterized major drug resistant mutations. Minor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Anti-HIV Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Deoxycytidine

Share to Emtricitabine

Share to Homosexuality, Male

Share to Organophosphonates

Share to Tenofovir

Share to Viral Load

Source

Open in PubMed Open full text

Identifiers

PMID: 24740633
DOI: 10.1093/infdis/jiu233
PMCID: PMC4176446

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial.PMID 24740633Read ↗

Drug resistance among patients who acquired HIV infection in a preexposure prophylaxis trial.Semantic proximity Read ↗

Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessationSemantic proximity Read ↗

Transmitted Drug Resistance Among Human Immunodeficiency Virus (HIV)-1 Diagnoses in the United States, 2014-2018.Semantic proximity Read ↗

Low clinical impact of HIV drug resistance mutations in oral pre-exposure prophylaxis: a systematic review and meta-analysis.Semantic proximity Read ↗

Pre-exposure Prophylaxis Use History in People With Antiretroviral Resistance at HIV Diagnosis: Findings From New York City HIV Surveillance and Partner Services, 2015-2022.Semantic proximity Read ↗

Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeqSemantic proximity Read ↗

Low prevalence of transmitted K65R and other tenofovir resistance mutations across different HIV-1 subtypes: implications for pre-exposure prophylaxis.Semantic proximity Read ↗

HIV-1 Drug Resistance Among Treatment-Naive Transgenders from India.Semantic proximity Read ↗

Transmitted, pre-treatment and acquired antiretroviral drug resistance among men who have sex with men and transgender women living with HIV in Nigeria.Semantic proximity Read ↗

Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case reportSemantic proximity Read ↗

Transmission of HIV-1 drug resistance mutations within partner-pairs: A cross-sectional study of a primary HIV infection cohort.Semantic proximity Read ↗

HIV pretreatment drug resistance among cisgender MSM and transgender women from Lima, Peru.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.